To enable delivery of IFN-α to lymphoma cells, with anti-CD20 antibody-IFN-α fusion proteins have been developed which show potent anti-lymphoma effects in pre-clinical models [115, 116]. This evidence concerns the gene IFNA1 and lymphoma.